The Phase 2 protocol (NEJM, 48 weeks)
The Phase 2 obesity trial randomized participants to placebo or retatrutide at four once-weekly target doses. The design detail most coverage misses: higher-dose arms reached their targets slowly.
| Target dose (weekly) | Starting dose | Escalation pattern | Mean weight change, 48 wk |
|---|---|---|---|
| 1 mg | 1 mg | none | -8.7% |
| 4 mg | 2 or 4 mg | step at 4 weeks | -17.1% |
| 8 mg | 2 or 4 mg | 4-week steps (2→4→8) | -22.8% |
| 12 mg | 2 mg | 4-week steps (2→4→8→12) | -24.2% |
| Placebo | - | - | -2.1% |
Two findings shaped the Phase 3 design. First, the dose-response was still separating at 48 weeks - the 12 mg curve had not plateaued. Second, arms starting at 2 mg tolerated escalation meaningfully better than arms starting at 4 mg, with fewer GI-driven discontinuations. Slow starts won.
What Phase 3 (TRIUMPH) changed
TRIUMPH protocols retained once-weekly dosing with gradual escalation, testing maintenance doses in the same range as Phase 2's upper arms. Exact Phase 3 titration schedules will define the eventual label if the drug is approved; final labeled dosing may differ from trial arms - it usually does.
Why once weekly: the pharmacology
Retatrutide is engineered as a fatty-acylated peptide that binds albumin, extending its half-life to roughly six days - the same design logic as semaglutide and tirzepatide. That half-life does two practical things: it makes once-weekly injection pharmacologically coherent (plasma levels stay in range between doses), and it means steady-state is only reached after four to five weeks at a given dose. That second point explains the trials' four-week escalation intervals: stepping up faster stacks a new dose on top of a still-rising plateau, which is where GI tolerance breaks.
After the target: maintenance, and what stopping does
Phase 2 ended at 48 weeks with the weight-loss curve still descending, so the true maintenance picture belongs to Phase 3 and its extensions. What the incretin class has already shown, however, is directly relevant: in withdrawal studies of semaglutide and tirzepatide, participants who stopped regained a large fraction - typically half to two-thirds - of lost weight within a year. There is no reason to expect the triple agonist to behave differently, and no data yet showing it does. Anyone modeling “a few months of retatrutide, then done” is modeling something the evidence contradicts across the entire drug class.
Handling and storage in the trials
The clinical program used pharmaceutical-grade solution in cold-chain custody - refrigerated storage, protected from light, with defined room-temperature excursions. Gray-market lyophilized vials have none of that history: unknown synthesis quality, unknown storage between manufacture and delivery, and reconstitution done at a kitchen table. Degradation doesn't announce itself; a vial that spent a week in a hot mail truck looks identical to a good one. That's a product-integrity argument, and it's also a math argument - a degraded vial makes every concentration calculation silently wrong.
The vial math people are actually searching for
The most common real-world question - “how much bac water for 10 mg of retatrutide” - has no single answer, because water volume only sets concentration:
| 10 mg vial + water | Concentration | 2 mg draw equals |
|---|---|---|
| 1 ml | 10 mg/ml | 0.2 ml = 20 units |
| 2 ml | 5 mg/ml | 0.4 ml = 40 units |
| 4 ml | 2.5 mg/ml | 0.8 ml = 80 units |
The retatrutide calculator runs this with your numbers, shows the syringe position visually, and flags draws too small or large to measure reliably. It never suggests a dose.
Frequently asked questions
What doses did the retatrutide trials use?
The Phase 2 trial tested 1, 4, 8, and 12 mg once weekly over 48 weeks. Higher-dose arms did not start at the target: the 8 mg and 12 mg arms began at 2 mg weekly, escalating every 4 weeks. Phase 3 TRIUMPH protocols continue the slow-escalation design.
Why does escalation matter so much with retatrutide?
In Phase 2, gastrointestinal side effects were concentrated during dose increases, and the arms that started at 2 mg (rather than 4 mg) tolerated escalation notably better. Escalation speed, not just target dose, drove tolerability.
How many units is a retatrutide dose on an insulin syringe?
It depends entirely on your vial's concentration. A 10 mg vial reconstituted with 2 ml of bacteriostatic water is 5 mg/ml, so 2 mg = 0.4 ml = 40 units. Change the water volume and the units change. Use the calculator with your actual numbers.
What was the highest retatrutide dose tested?
12 mg once weekly was the highest maintenance dose in the Phase 2 obesity trial, reached via 4-week escalation steps from a 2 mg start. Phase 3 maintenance doses sit in the same range; no published trial has tested higher chronic doses.
What happens when you stop retatrutide?
No retatrutide-specific withdrawal data exists yet. Across the incretin class (semaglutide, tirzepatide), stopping led to regaining roughly half to two-thirds of lost weight within a year in withdrawal studies. The default assumption is that retatrutide behaves like its class until shown otherwise.
Sources: Jastreboff et al., NEJM (Phase 2 obesity trial); registered TRIUMPH Phase 3 protocols; FDA statements on unapproved GLP-1 products. Continue with side effects or the approval tracker.